ROCKVILLE, Md.--(BUSINESS WIRE)--Celera Group (NYSE:CRA), an Applera Corporation business, today reported a net loss of $7.8 million, or $0.10 per share, for the fourth quarter of fiscal 2007 ended June 30, 2007, compared to a net loss of $5.3 million, or $0.07 per share, for the fourth quarter of fiscal 2006. The fourth quarter fiscal 2007 results included pre-tax restructuring charges of $3.8 million for an additional asset impairment associated with the previous decision to exit small molecule drug discovery and development and $0.5 million for employee-related costs, primarily severance. The fourth quarter fiscal 2006 results included a $5.3 million pre-tax charge for restructuring costs associated with the decision to exit small molecule drug discovery and development and the integration of Celera Diagnostics into Celera. The fourth quarter 2006 results also included revenue of $8.6 million from the sale of certain small molecule drug discovery and development programs. All per share amounts refer to Applera Corporation-Celera Group Common Stock.
